137 related articles for article (PubMed ID: 35349822)
1. Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer.
Shui X; Ren X; Xu R; Xie Q; Hu Y; Qin J; Meng H; Zhang C; Zhao J; Shi C
Biochem Biophys Res Commun; 2022 May; 606():135-141. PubMed ID: 35349822
[TBL] [Abstract][Full Text] [Related]
2. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
3. MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells.
Lin YC; Chang YT; Campbell M; Lin TP; Pan CC; Lee HC; Shih JC; Chang PC
Sci Rep; 2017 Apr; 7():46338. PubMed ID: 28402333
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
Han H; Li H; Ma Y; Zhao Z; An Q; Zhao J; Shi C
Cancer Lett; 2023 Jun; 563():216188. PubMed ID: 37076041
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
7. Targeting monoamine oxidase A in advanced prostate cancer.
Flamand V; Zhao H; Peehl DM
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1761-71. PubMed ID: 20204405
[TBL] [Abstract][Full Text] [Related]
8. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
Wei J; Yin L; Li J; Wang J; Pu T; Duan P; Lin TP; Gao AC; Wu BJ
Cancer Res; 2021 Aug; 81(16):4275-4289. PubMed ID: 34167949
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Wu JB; Shao C; Li X; Li Q; Hu P; Shi C; Li Y; Chen YT; Yin F; Liao CP; Stiles BL; Zhau HE; Shih JC; Chung LW
J Clin Invest; 2014 Jul; 124(7):2891-908. PubMed ID: 24865426
[TBL] [Abstract][Full Text] [Related]
11. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
[TBL] [Abstract][Full Text] [Related]
12. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
13. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
14. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth.
Wu JB; Lin TP; Gallagher JD; Kushal S; Chung LW; Zhau HE; Olenyuk BZ; Shih JC
J Am Chem Soc; 2015 Feb; 137(6):2366-74. PubMed ID: 25585152
[TBL] [Abstract][Full Text] [Related]
17. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
[TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling.
Du Y; Long Q; Zhang L; Shi Y; Liu X; Li X; Guan B; Tian Y; Wang X; Li L; He D
Int J Oncol; 2015 Dec; 47(6):2064-72. PubMed ID: 26499200
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration.
Jacobs MR; Olivero JE; Ok Choi H; Liao CP; Kashemirov BA; Katz JE; Gross ME; McKenna CE
Bioorg Med Chem; 2023 Sep; 92():117425. PubMed ID: 37544256
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
Zhu S; Tian H; Niu X; Wang J; Li X; Jiang N; Wen S; Chen X; Ren S; Xu C; Chang C; Flores-Morales A; Shang Z; Sun Y; Niu Y
Oncogene; 2019 Jun; 38(24):4875-4884. PubMed ID: 30770901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
